Gardia Medical specializes in the development of catheter-based delivery systems that easily integrate with the standard workflow of stenting and other cardiovascular intervention procedures. Gardia is currently introducing the first wire-independent distal filtration Embolic Protection Device (EPD). Compatibility with standard guide wires and the seamless integration with interventional procedure workflow promises to set a new standard for the cardiovascular intervention field.

EPD's are known to reduce the incidence of embolic complications during catheter-based procedures such as carotid and SVG angioplasty. However, physicians looking to use EPD's today face a number of challenges, the first being the need to use dedicated guide wires which can be difficult to maneuver, and lead to more complex, costly and lengthy procedures.

The Gardia EPD rapid exchange delivery system locks the stand-alone filter unit onto any standard guide wire, allowing the clinician to use his/her wire of choice. Unlike other devices, the Gardia EPD filter is not pre-attached to the distal end of the guide wire. It can be positioned anywhere along the vessel to ensure maximal side branch protection.

Gardia Medical's proprietary technology is designed for use in a variety of applications in the field of interventional medicine.

Gardia Medical is a privately-held company founded in 2006. Uri Rosenschein MD co-founded the company with Medica Venture Partners, Israel's oldest & largest healthcare dedicated venture capital fund.